Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	1 To evaluate the efficacy of marketed colchicine 0.5 mg plus marketed Aspirin 75 mg given twice daily at the same time in the management <br/ >of inflammation and thrombotic condition of <br/ >moderate COVID-19 disease through the <br/ >specific biomarkers <br/ >2. To evaluate the symptomatic improvement <br/ >through the NEWS score and 8-point ordinal <br/ >scoreTimepoint: First Treatment day up to 15 days	1 To evaluate the efficacy of marketed colchicine 0.5 mg plus marketed Aspirin 75 mg given twice daily at the same time in the management <br/ >of inflammation and thrombotic condition of <br/ >moderate COVID-19 disease through the <br/ >specific biomarkers <br/ >2. To evaluate the symptomatic improvement <br/ >through the NEWS score and 8-point ordinal <br/ >scoreTimepoint: First Treatment day up to 15 days
Nov. 13, 2021, 5:33 p.m.	oms	N/A	N/A
March 26, 2021, 2:21 p.m.	oms	1 To evaluate the efficacy of marketed colchicine 0.5 mg plus marketed Aspirin 75 mg given twice daily at the same time in the management <br/ >of inflammation and thrombotic condition of <br/ >moderate COVID-19 disease through the <br/ >specific biomarkers <br/ >2. To evaluate the symptomatic improvement <br/ >through the NEWS score and 8-point ordinal <br/ >scoreTimepoint: First Treatment day up to 15 days	1 To evaluate the efficacy of marketed colchicine 0.5 mg plus marketed Aspirin 75 mg given twice daily at the same time in the management <br/ >of inflammation and thrombotic condition of <br/ >moderate COVID-19 disease through the <br/ >specific biomarkers <br/ >2. To evaluate the symptomatic improvement <br/ >through the NEWS score and 8-point ordinal <br/ >scoreTimepoint: First Treatment day up to 15 days